共 108 条
[11]
James R.D.(2005)Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 3697-65
[12]
Karasek P.(2003)Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60-1544
[13]
Fujishima H.(2007)Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539-1214
[14]
Kikuchi I.(2007)Bevacizumab in combination with XELOX or FOLFOX: updated efficacy results from XELOX-1/N016966, a randomized phase III trial in first line metastatic colorectal cancer Proc Am Soc Clin Oncol 170s 4028-237
[15]
Miyanaga O.(2004)Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 1209-159
[16]
Ueda A.(2002)Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol 21 129a-400
[17]
Baba E.(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229-undefined
[18]
Mitsugi K.(2006)Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study) Cancer Invest 24 154-undefined
[19]
Goto A.(2006)OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study J Clin Oncol 24 394-undefined
[20]
Yamada Y.(2007)Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (2nd report): For Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Proc Am Soc Clin Oncol 25 18S-undefined